Generated by AI
BioMarin Pharmaceutical Inc. is a global biotechnology company focused on developing and commercializing therapies for rare genetic and metabolic diseases. Its portfolio includes approved medicines and advanced treatments such as enzyme replacement therapies, gene therapies, and other specialized biologics designed for patients living with genetically defined conditions. BioMarin’s products are used in areas including lysosomal storage disorders, achondroplasia, hemophilia, phenylketonuria, and other serious rare diseases. The company serves a specialized role in the healthcare market by addressing conditions that often have limited treatment options, with a business model centered on research, regulatory development, manufacturing, and global commercialization of orphan-disease therapies. Headquartered in San Rafael, California, BioMarin Pharmaceutical Inc. is recognized as a leading rare disease biotechnology company.
Website770 Lindaro Street
San Rafael, CA, 94901
United States
The latest articles about BMRN.
Summary of Nov 2's posts. Generated by AI.
Summary of Dec 19's posts. Generated by AI.
Summary of Nov 22's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Investors talking about BMRN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.